CSIMarket Company Name, Ticker, Competitors, else..


Intellia Therapeutics Inc   (NASDAQ: NTLA)
Other Ticker:  
 

Intellia Therapeutics Inc

NTLA's Fundamental analysis



Looking into Intellia Therapeutics Inc growth rates, revenue grew by 51.27 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 265

In Vitro & In Vivo Diagnostic Substances industry recorded growth of revenues by 3.57 %

Intellia Therapeutics Inc net loss decreased from $-136 millions, to $-101 millions in third quarter of 2025,

• More on NTLA's Growth


Intellia Therapeutics Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 14.46 in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 18.41.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.62.


• More on NTLA's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 479,400
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 5.56
 Tangible Book Value (Per Share $) 6.79

Intellia Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 14.46 in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 18.41.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.62.

Intellia Therapeutics Inc Price to Book Ratio is at 1.41 lower than Industry Avg. of 776.93. and higher than S&P 500 Avg. of 0.02

• More on NTLA's Valuation

•  Market Capitalization (Millions $) 1,059
•  Shares Outstanding (Millions) 110
•  Employees 120
•  Revenues (TTM) (Millions $) 58
•  Net Income (TTM) (Millions $) -446
•  Cash Flow (TTM) (Millions $) 73
•  Capital Exp. (TTM) (Millions $) -2
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 479,400
•  Net Income/Employee(TTM) $ -
•  Receivable Turnover Ratio (TTM) 5.56
•  Tangible Book Value (Per Share $) 6.79

•  Market Capitalization (Millions $) 1,059
•  Shares Outstanding (Millions) 110
•  Employees 120
•  Revenues (TTM) (Millions $) 58
•  Net Income (TTM) (Millions $) -446
•  Cash Flow (TTM) (Millions $) 73
•  Capital Exp. (TTM) (Millions $) -2





  Ratio
•   Capital Ratio (MRQ) 6.21
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.24
•  Asset Turnover Ratio (TTM) 0.07
•  Inventory Turnover Ratio (TTM) -





Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.